anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the use of derivatives of F-type prostaglandins a s ocular hypotensives. The PGF derivatives used in accordance with the inventi on are represented by formula (I), wherein wavy line attachments indicate either th e alpha .alpha. or beta .beta. configuration; hatched segments indicate .alpha. configuration; solid triangles are used to indicate .beta. configuration, dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R1 is hydrogen or a lowe r alkyl radical having up to six carbon atoms, X is selected from the group consisti ng of -OR1 and -N(R1)2, Y is = O or represents 2 hydrogen radicals. Certain of the compounds represented by formula (I) comprise another aspect of the present invention.
To promote adherence and reduce social isolation, participants will be asked to use home-based cognitive training program on a tablet for 30 minutes per day for 5 days a week for 1 month, then use it freely for another month. The cognitive training program has a chat function and a leadership board to allow interaction between participants.
V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
PURPOSE:To obtain a solid or semi-solid external drug for skin having excellent transparency, applicability and ultraviolet-shielding effect by using methylphenylpolysiloxane in combination with N-lauroyl-L-glutamic acid dibutylamide. CONSTITUTION:The objective external drug for skin is produced by compounding methylphenylpolysiloxane with N-lauroyl-L-glutamic acid dibutylamide. The drug has excellent transparency and a certain degree of hardness and exhibits smooth spreadability and excellent applicability in spite of its solid or semi-solid nature. The hardness and transparency can be further increased without deteriorating the applicability by adding 12-hydroxystearic acid together with the above two components. It is also preferable to add an ultraviolet absorber together with the two components. The two components may be compounded with both of the 12-hydroxystearic acid and the ultraviolet absorber.
Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligpeptide and optionally a carrier comprising a positively charged æbackboneÆ having positively charged branching or æefficiencyÆ groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidly polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment. This invention also provides kits for preparing or formulating a composition that comprises the oligopeptide and optionally a carrier, as well as such additional items that are needed to produce a usable formulation, or a premix that may in turn be used to produce such a formulation. Fig. No. 1a
Levetiracetam extended-release tablets can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in white blood cell (WBC), neutrophil, and red blood cell (RBC) counts; decreases in hemoglobin and hematocrit; and increases in eosinophil counts. Cases of agranulocytosis, pancytopenia, and thrombocytopenia have also been reported in the postmarketing setting. A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders.

In controlled trials of immediate-release levetiracetam tablets in patients experiencing partial-onset seizures, minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 x 106/mm3), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in immediate-release levetiracetam tablets-treated patients.

A total of 3.2% of levetiracetam-treated and 1.8% of placebo-treated patients had at least one possibly significant (≤ 2.8 x 109/L) decreased WBC, and 2.4% of levetiracetam-treated and 1.4% of placebo-treated patients had at least one possibly significant (≤ 1.0 x 109/L) decreased neutrophil count. Of the levetiracetam-treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.

In pediatric patients (4 to < 16 years of age), statistically significant decreases in WBC and neutrophil counts were seen in patients treated with immediate-release levetiracetam tablets, as compared to placebo. The mean decreases from baseline in the immediate-release levetiracetam tablets group were -0.4 × 109/L and -0.3 × 109/L, respectively, whereas there were small increases in the placebo group. A significant increase in mean relative lymphocyte counts was observed in 1.7% of patients treated with immediate-release levetiracetam tablets compared to a decrease of 4% in patients on placebo.

In the controlled pediatric trial, a possibly clinically significant abnormal low WBC value was observed in 3% of patients treated with immediate-release levetiracetam tablets, compared to no patients on placebo. However, there was no apparent difference between treatment groups with respect to neutrophil count. No patient was discontinued secondary to low WBC or neutrophil counts.

In the controlled pediatric cognitive and neuropsychological safety study, two subjects (6.1%) in the placebo group and 5 subjects (8.6%) in the immediate-release levetiracetam tablets-treated group had high eosinophil count values that were possibly clinically significant (≥ 10% or ≥ 0.7X109/L).
Devices and methods for rendering an intravascular device such as a stent radioactive in-situ, after placement. A device is provided having a surface (20) and a first substance (22) immobilized thereon. The first substance (22) preferably has a high and selective affinity for a second substance (26) which can be radioactive, cytotoxic or thrombolytic. The first substance (22) can also have an affinity for growth factors or thrombolytic, chemolytic or cytotoxic agents. The device can be placed across a stenosed blood vessel region, preferably after dilation by angioplasty or atherectomy. After device placement within the vessel, the second substance (26) can be injected into the blood stream of a patient. With each pass through the device, the second substance (26) is increasingly bound to the first substance (22) on the device surface (20). Suitable complementary substance pairs include avidin and radiolabeled biotin, protamine and radioactive heparin, and protein and antiprotein antibody.
A resin drug adsorbate comprises a cross-linked polystyrene/divinyl benzene nuclear sulphonic acid cation exchange resin, e.g. in micropowdered form, in which at least some of the cations, e.g. 25-38%, present are cations of amprotropine:-  <FORM:0925890/IV(a)/1> The adsorbate may be made by charging at 15-25 DEG C. an aq. solution of an amprotropine salt, e.g. phosphate or a water-soluble mineral acid (e.g. HCl) salt, to the resin, which may be in an alkali metal, e.g. Na, or H2 cycle, until the mixture reaches equilibrium; the mixture is then filtered and the resin dried, e.g. at 45 DEG C., and may then be ground in a mill.  An pharmaceutical adjuvant may be used in admixture with the adsorbate.  Specification 577,707 is referred to.ALSO:Pharmaceutical compositions for slow oral injestion comprise a cross-linked polystyrene/divinyl benzene nuclear sulphonic acid cationexchange resin in which at least some of the cations present are those of amprotropine having the formula <FORM:0925890/VI/1> Examples of compositions relate to tablets comprising the above resin/drug adsorbate alone and together with (a) an antacid composition comprising aluminium hydroxide and magnesium trisilicate and which may also comprise phenindamine tartrate; (b) an antacid composition comprising dihydroxy aluminium aminoacetate and which may also comprise phenobarbitol or acetyl salicylic acid; (c) acetyl-salicylic acid, acetophenetidin and caffeine and which may also comprise phenindamine tartrate alone and with phenylephrine hydrochloride and (d) acetophenelidin, caffeine and isopropyl-antipyrine.  Specification 577,707 is referred to.
The invention is concerned with a method of contraception in a female mammal of childbearing capability, said method consisting of two alternating phases -a preservation phase and a shedding phase - and comprising at least two sequences of (~a). a preservation phase of 3 -12 months comprising continuous oral administration to the female of dosage units containing: (i) an estrogen selected from the group consisting of 17.beta.-estradiol, esters of 17.beta. -estradiol and combinations thereof, in an amount equivalent to a daily oral dosage of 2.2-5 mg 17.beta. -estradiol, and (ii) a progestogen in an amount equivalent to a daily oral dosage of 30-750 ~g levonorgestrel; and (b). a shedding phase of 4-12 days during which no progestogen is administered. The invention also relates to a contraceptive kit comprising one or more packaging units comprising separately packaged, individually removable oral dosage units for use in the aforementioned contraceptive method.
Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
BACKGROUND: Fat distribution is closely related to vascular stiffness. This study aimed to investigate age and sex differences in fat distribution and brachial-ankle pulse wave velocity (baPWV), and the association between fat parameters and baPWV.
METHODS: A total of 10,811 participants aged 20-59 years were recruited. Measures included waist and hip circumference, waist-to-hip ratio (WHR), body mass index (BMI), percentage body fat (PBF), subcutaneous fat area (SFA), visceral fat area (VFA), and baPWV.
RESULTS: The results confirm that fat accumulates with age and that men tend to carry more abdominal fat than women in the same age group. The findings also indicate that baPWV increases with age and is significantly higher in men than in women in the same age group. In addition, WHR, VFA, and baPWV were more strongly correlated than baPWV and BMI, SFA, and PBF. Finally, the effects of age, PBF, WHR, and VFA on baPWV were greater for the higher quantiles.
CONCLUSIONS: There are age and sex differences in fat distribution and baPWV. Abdominal obesity is more closely linked to arterial stiffness than overall obesity, and people with higher baPWV are more affected by obesity parameters.
A medical system comprises a flexible device configured to be positioned at least partially within a patient anatomy. The patient anatomy includes a plurality of anatomical passageways. The medical system further comprises a memory device including computer executable instructions, the computer executable instructions for performing operations. The operations comprise determining a shape of the flexible device and determining a deformation force for a section of the flexible device. The operations further comprise registering a model of a candidate anatomical passageway of the plurality of anatomical passageways to a model of the flexible device based on the shape of the flexible device and the deformation force for the section of the flexible device. The operations further comprise generating a composite model of the patient anatomy based on the registering.
Optimal management of breast cancer-related lymphoedema (BCRL), a common and debilitating complication of surgery and radiotherapy, depends on early detection, personalised risk assessment and proactive intervention. For instance, a recent review advises healthcare professionals to reframe the narrative about the daily-living skin trauma risks away from 'what to avoid' to 'what to do'. Another review recommends daily, or nearly daily, exercise at home to reduce lymphoedema severity. However, several questions await full answers. There is, for instance, no consensus regarding the most appropriate surgical technique for preventing BCRL. This feature summarises some recent papers updating healthcare professionals about BCRL.
RNA interference (RNAi) has become a powerful tool for blocking gene expression in mammals and mammalian cells. This approach requires the delivery of small interfering RNA (siRNA) either as RNA itself or as DNA, using an expression plasmid or virus and the coding sequence for small hairpin RNAs that are processed to siRNAs. Current expression systems for the production of siRNA in vivo rely on RNA polymerase III promoters. These are difficult to regulate and leave most of the RNA in the nucleus of the cell where it is inactive for RNA interference. The invention provides a DNA cassette for the cloning of small hairpin sequences which permit their expression and processing using RNA polymerase II. This system enables efficient transport of the pre-siRNAs to the cytoplasm where they are active and permits the use of regulated and tissue specific promoters for gene expression.
BACKGROUND: Dysregulation of the airway microbiota is thought to contribute to airway inflammation in both chronic rhinosinusitis (CRS) and asthma. However, the relationship between the upper and lower airway microbiome remains unclear.
METHODS: Sinus and lung brushes were collected from 29 CRS participants undergoing sinus surgery. DNA was extracted and submitted for 16s rRNA microbiome sequencing. Alpha and beta diversity metrics, taxonomic composition, and differences between individual taxa were compared for paired sinus and bronchial samples.
RESULTS: Twenty-three out of 29 participants had sufficient samples for analysis. The mean (standard deviation) age was 51.59 (14.57) years, and 10 (44%) patients were female. Twelve (52%) patients had comorbid asthma. Sinus brushes had significantly higher alpha diversity indexes (Shannon and Faith) compared to bronchial brushes (p < 0.001). Beta diversity metrics were significantly different between the sinus and bronchial samples. Principal coordinate analysis showed no clustering of paired nasal and bronchial samples. Sinus brushes had significantly more Lawsonella, Corynebacterium, and Staphylococcus compared to bronchia brushes, while the latter were enriched in Tropheryma and Sphingomonas, among others (false discovery rate [FDR]-adjusted p < 0.01). Finally, CRS patients with comorbid asthma had significantly higher Pseudomonas and Peptoniphilus in sinus brushes and lower Prevotella in bronchial brushes when compared to non-asthmatics (FDR-adjusted p < 0.01).
CONCLUSION: The sinus and bronchial bacterial microbiomes differ in important ways. Our study suggests that migration of bacteria from the sinus into the lower airways is unlikely in patients with CRS.
For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
Aq. compsns. for injection, having a prolonged duration of action, contain the peptide of formula (I) H.Ala.Gly.Cys.Lys.Asn.Phe.Phe.Trp.Lys.Thr.Phe.Thr.Ser.Cys.OH (I) in the form of a complex produced by adding an inorg. salt (esp. halides, phosphates, pyro-phosphates or polyphosphates) of Ca, Co, Mg, Mn, Al or Zn; and/or a polymer such as polyoxygelatine, polyvinyl-pyrrolidone, carboxymethyl-cellulose or sulphnoc acid or phosphoric acid esters of alginic acid, dextran, polyphenols or polyalcohols. Esp. pref. is the addition of polyphloretin phosphate to (I). (I) inhibits are secretion of growth hormone but the action is short-lived when (I) is used as such. As a complex its activity persists for many hours. The compsns. are used for treating diabetes mellitus, acromegalia, and angiopathia and as diagnostic reagents.
General Considerations

The workup and treatment of candidates for clomiphene citrate therapy should be supervised by physicians experienced in management of gynecologic or endocrine disorders. Patients should be chosen for therapy with clomiphene citrate only after careful diagnostic evaluation (see INDICATIONS AND USAGE). The plan of therapy should be outlined in advance. Impediments to achieving the goal of therapy must be excluded or adequately treated before beginning clomiphene citrate. The therapeutic objective should be balanced with potential risks and discussed with the patient and others involved in the achievement of a pregnancy. 

Ovulation most often occurs from 5 to 10 days after a course of clomiphene citrate. Coitus should be timed to coincide with the expected time of ovulation. Appropriate tests to determine ovulation may be useful during this time. 

  


Recommended Dosage 

Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tablet) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg clomiphene citrate. A low dosage or duration of treatment course is particularly recommended if unusual sensitivity to pituitary gonadotropin is suspected, such as in patients with polycystic ovary syndrome (see WARNINGS; Ovarian Hyperstimulation Syndrome). 

The patient should be evaluated carefully to exclude pregnancy, ovarian enlargement, or ovarian cyst formation between each treatment cycle.

  


If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs prior to therapy, the regimen of 50 mg daily for 5 days should be started on or about the 5th day of the cycle. Therapy may be started at any time in the patient who has had no recent uterine bleeding. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment. 

If ovulation does not appear to occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended. 

The majority of patients who are going to ovulate will do so after the first course of therapy. If ovulation does not occur after three courses of therapy, further treatment with clomiphene citrate is not recommended and the patient should be reevaluated. If three ovulatory responses occur, but pregnancy has not been achieved, further treatment is not recommended. If menses does not occur after an ovulatory response, the patient should be reevaluated. Long-term cyclic therapy is not recommended beyond a total of about six cycles (see PRECAUTIONS).
Theory of mind (TOM) refer to the cognitive ability to attribute mental states to others, which plays an essential role in social communications and interactions between individuals. In several recent papers, it was shown that TOM is impaired in schizophrenia and bipolar disorder. This impairment strongly affects the quality of life in patients suffering from these disorders. The investigators study aims to explore the neural correlates of TOM in schizophrenic and bipolar patients, in comparison with those of healthy participants. These studies will be conducted on 30 schizophrenic patients, 30 bipolar patients, and 60 healthy participants, matched on age and educational level to each patient group. The investigators expect that the study of combined behavioral (neuropsychological tests) and neuro-anatomical data will allow to understand the pathophysiology of the alteration of social cognition processes in these illnesses.
Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
A prospective cohort study utilizing a pre-test/post-test design will be used to test a COPD education intervention on a convenience sample of 30 patients with a diagnosis of COPD. Study participants will complete the Chronic Obstructive Pulmonary Disease questionnaire (COPD-Q) to assess their COPD knowledge. Next, a respiratory therapist will provide the first scripted COPD education session. The patient will complete the COPD-Q 24 hours and 30 days post-discharge. Demographic data, smoking status, pack-years, COPD spirometry grade, COPD symptom and exacerbation grade, previous hospital admissions, support system for managing COPD, attendance at previous formal education for COPD, current and home medications, pulmonary function test (PFT) results, vaccinations, and level of education data will be collected. Data related to patient recruitment will also be collected. Means and standard deviation will be reported for interval data. Total frequency and percentages will be reported for nominal data, and median and 25th and 75th percentile will be reported for COPD severity. Repeated measures ANOVA (p\< 0.05) will be used to evaluate if an inpatient COPD self-management intervention can increase the patient's knowledge of COPD after 24 hours and again at 30 days after the initial education session.

This study is expected to show that an inpatient education of COPD can increase the patient's COPD knowledge prior to discharge and that it will be retained for at least one month post-discharge.
A multifunction composite for delivering contrast and drug is provided to progress diagnosis and treatment at the same time by performing delivery of contrast and drug in one system and to have high pharmacological efficacy in low capacity. A multifunction composite for delivering contrast and drug comprises a plurality of nano particles. The nano particle comprises a signal generating core and water soluble polymer outer shell. The water soluble polymer outer shell comprises a surface anchoring site and a drug combining portion. The water soluble polymer outer shell is coated on the surface of the signal generation core. The surface anchoring site comprises silyl-, hydroxy silyl- or alkoxysilyl-functional. The signal generation core is paramagnetic, superparamagnetic or proton density signal generation core.